Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"CD52"”.
-
Lymphodepletion with repeated cycles of alemtuzumab and secondary autoimmunity after alemtuzumab treatment of relapsing-remitting multiple sclerosis
… and mortality. The lymphocyte depleting, anti-CD52 monoclonal antibody alemtuzumab is a highly effective treatment option in RRMS, though associated with high rates of secondary autoimmune disorders. As alemtuzumab is now in routine clinical use, following licensing in Europe and the US, …
-
Synthesis Of Functionalized Gpi Anchors And Related Glycoconjugates
… to a GPI-anchored molecule, namely the human CD52 antigen, which is a 12-amino acid glycopeptide containing a single N-glycosylation site, to which complex glycans are attached. This glycoconjugate exists in two distinct functional forms, including lymphocyte and sperm CD52, which are involved …
-
Studying the B and plasma cell responses to the immune checkpoint blockade treatment of cancer
… the expression of the immune-modulator Cd52 distinguished between B and plasma cell clusters that were phenotypically similar but spatially separate on the UMAP plot. CD52-low naïve B cells downregulated IGHM, indicative of an anergic phenotype. CD52-low germinal centre B cells displayed …
-
Modeling hematologic malignancies and their treatment in humanized mice
… cells that arise in these mice expressed CD52 and were transplantable into secondary recipients; these were subsequently used to test the efficacy of a human specific monoclonal antibody to CD52, alemtuzumab, which is currently approved for treatment of chronic lymphocytic leukemia, but …
-
Immunogeneic Cell Populations of the Skin
… monoclonal antibodies. Alemtuzumab (anti-CD52) is a monoclonal antibody and has proven effective in preventing aGvHD after aHSCT. It may, despite depleting donor T cells, also work by targeting recipient DCs. To determine whether the last mechanism of action is significant, a second …